297 related articles for article (PubMed ID: 34452063)
1. Risk Factors Associated with the Clinical Outcomes of COVID-19 and Its Variants in the Context of Cytokine Storm and Therapeutics/Vaccine Development Challenges.
Hanna J; Tipparaju P; Mulherkar T; Lin E; Mischley V; Kulkarni R; Bolton A; Byrareddy SN; Jain P
Vaccines (Basel); 2021 Aug; 9(8):. PubMed ID: 34452063
[TBL] [Abstract][Full Text] [Related]
2. Current Strategies of Antiviral Drug Discovery for COVID-19.
Mei M; Tan X
Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887
[TBL] [Abstract][Full Text] [Related]
3. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.
Gong W; Parkkila S; Wu X; Aspatwar A
Int Rev Immunol; 2023; 42(6):393-414. PubMed ID: 35635216
[TBL] [Abstract][Full Text] [Related]
5. COVID-19: Discovery, diagnostics and drug development.
Asselah T; Durantel D; Pasmant E; Lau G; Schinazi RF
J Hepatol; 2021 Jan; 74(1):168-184. PubMed ID: 33038433
[TBL] [Abstract][Full Text] [Related]
6. A Network-Based Analysis Reveals the Mechanism Underlying Vitamin D in Suppressing Cytokine Storm and Virus in SARS-CoV-2 Infection.
Ahmed F
Front Immunol; 2020; 11():590459. PubMed ID: 33362771
[TBL] [Abstract][Full Text] [Related]
7. COVID-19: Prospective Challenges and Potential Vaccines.
Shahid Nadeem M; Ali A; Al-Ghamdi MA; Depfenhart M; Azam Khan J; Zamzami MA; Nazia Murtaza B; Kazmi I; Ur Rehman M
Altern Ther Health Med; 2020 Aug; 26(S2):72-78. PubMed ID: 32845250
[TBL] [Abstract][Full Text] [Related]
8. An Immunological Review of SARS-CoV-2 Infection and Vaccine Serology: Innate and Adaptive Responses to mRNA, Adenovirus, Inactivated and Protein Subunit Vaccines.
Al-Sheboul SA; Brown B; Shboul Y; Fricke I; Imarogbe C; Alzoubi KH
Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679897
[TBL] [Abstract][Full Text] [Related]
9. Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination.
Zheng C; Kar I; Chen CK; Sau C; Woodson S; Serra A; Abboud H
CNS Drugs; 2020 Sep; 34(9):879-896. PubMed ID: 32780300
[TBL] [Abstract][Full Text] [Related]
10. Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review.
Quirch M; Lee J; Rehman S
J Med Internet Res; 2020 Aug; 22(8):e20193. PubMed ID: 32707537
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2: pathogenesis, therapeutics, variants, and vaccines.
Li X; Mi Z; Liu Z; Rong P
Front Microbiol; 2024; 15():1334152. PubMed ID: 38939189
[TBL] [Abstract][Full Text] [Related]
12. Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions.
Jafarzadeh A; Chauhan P; Saha B; Jafarzadeh S; Nemati M
Life Sci; 2020 Sep; 257():118102. PubMed ID: 32687918
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.
Fenizia C; Galbiati S; Vanetti C; Vago R; Clerici M; Tacchetti C; Daniele T
Microbiol Spectr; 2022 Feb; 10(1):e0150421. PubMed ID: 34985303
[TBL] [Abstract][Full Text] [Related]
14. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
[TBL] [Abstract][Full Text] [Related]
15. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
16. Targeting the SphK-S1P-SIPR Pathway as a Potential Therapeutic Approach for COVID-19.
McGowan EM; Haddadi N; Nassif NT; Lin Y
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33003377
[TBL] [Abstract][Full Text] [Related]
17. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
[TBL] [Abstract][Full Text] [Related]
18. Molecular Pathogenesis, Immunopathogenesis and Novel Therapeutic Strategy Against COVID-19.
Chatterjee SK; Saha S; Munoz MNM
Front Mol Biosci; 2020; 7():196. PubMed ID: 32850977
[TBL] [Abstract][Full Text] [Related]
19. Current status in cellular-based therapies for prevention and treatment of COVID-19.
Hattab D; Amer MFA; Mohd Gazzali A; Chuah LH; Bakhtiar A
Crit Rev Clin Lab Sci; 2023 Aug; 60(5):321-345. PubMed ID: 36825325
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
Elife; 2022 Feb; 11():. PubMed ID: 35191378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]